Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs

Acta Pharmacologica Sinica

Volumn 34, Issue 11, 2013, Pages 1420-1426

  Zhou, Xin ^a   Gao, Zhi Wei ^a   Meng, Jian ^a   Chen, Xiao Yan ^a   Zhong, Da Fang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

CYP3A; Drug drug interaction; GLS4; Hepatitis B virus; Ketoconazole; Rifampicin

Indexed keywords

ANTIVIRUS AGENT; CYTOCHROME P450 3A4; GLS 4; KETOCONAZOLE; MORPHOLINE; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DOGS; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MICROSOMES, LIVER; PYRIMIDINES; RIFAMPIN; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; THIAZOLES;

EID: 84887396506     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.76     Document Type: Article

References (28)

1. Institute of Medicine (IOM). Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010.
2. World Health Organization. Fact Sheet #204: Hepatitis B. 2012 July [cited 2013 Feb 23]. Available from: http://www.who.int/mediacentre/factsheets/fs204/ en/index.html.
3. Loomba R, Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther 2006; 11: 1-15.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41. (Pubitemid 33096596)
5. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96. (Pubitemid 36337972)
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81. (Pubitemid 41007822)
7. Deres K, Schröder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-6. (Pubitemid 36182448)
8. Wang XY, Wei ZM, Wu GY, Wang JH, Zhang YJ, Li J, et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 2012; 17: 793-803.
9. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32. (Pubitemid 36759050)
10. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448. (Pubitemid 34311090)
11. Achira M, Suzuki H, Ito K, Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1999; 1: E18.
12. Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev 2004; 36: 497-509. (Pubitemid 39456439)
13. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461-71.
14. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-8. (Pubitemid 28189400)
15. FDA, Guidance for industry (draft) drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. 2012 Feb [cited 2013 Feb 23]. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
16. Baxter JG, Brass C, Schentag JJ, Slaughter RL. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sci 1986; 75: 443-7. (Pubitemid 16083637)
17. Kyokawa Y, Nishibe Y, Wakabayashi M, Harauchi T, Maruyama T, Baba T, et al. Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. Chem Biol Interact 2001; 134: 291-305. (Pubitemid 32406151)
18. Fraser DJ, Feyereisen R, Harlow GR, Halpert JR. Isolation, hetero-logous expression and functional characterization of a novel cyto-chrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 1997; 283: 1425-32. (Pubitemid 28016518)
19. Kuroha M, Kuze Y, Shimoda M, Kokue E. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. Am J Vet Res 2002; 63: 900-5. (Pubitemid 34624962)
20. Kuroha M, Shirai Y, Shimoda M. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs. J Vet Pharmacol Ther 2004; 27: 355-9. (Pubitemid 39482240)
21. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996; 24: 1121-3. (Pubitemid 26346226)
22. Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, Kokue E. Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 2002; 91: 868-73. (Pubitemid 34639649)
23. Lamberg TS, Kivistö KT, Neuvonen PJ. Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 1998; 45: 381-5. (Pubitemid 28138831)
24. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 387-9. (Pubitemid 26284429)
25. Boxenbaum H. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 1999; 2: 47-52.
26. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994; 34: 1222-7.
27. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8. (Pubitemid 23086411)
28. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189: 51-60. (Pubitemid 38122329)